

Fiscal Year 2011 Annual Review of Select Anti-Emetics

Oklahoma HealthCare Authority

April 2012

Current Prior Authorization Criteria

Approval Criteria for granisetron (Kytril® and Sancuso®), dolasetron (Anzemet®), and aprepitant (Emend®):

1. Approved Diagnosis
2. A recent (within the past 6 months) trial of ondansetron used for at least 3 days or one cycle that resulted in inadequate response.
3. Approval length based on duration of need.
4. Quantity limits apply.

Approval Criteria for cannabinoids (Marinol® and Cesamet®):

1. For the diagnosis of HIV related loss of appetite: approve for 6 months
2. For chemotherapy induced nausea and vomiting: A recent (within the past 6 months) trial of ondansetron used for at least 3 days or one cycle that resulted in inadequate response.
3. Approval length based on duration of need.
4. A quantity limit of 60 per 30 days also applies.


Approval Criteria for ondansetron soluble film (Zuplenz™):

- FDA-approved indication.
- Must provide a clinically significant reason why the member cannot take all other available formulations of generic ondansetron.


Utilization of Select Anti-Emetics

Fiscal Year	Members	Claims	Cost	Cost/Claim	Perdiem	Units	Days
2010	21,040	27,907	\$600,424.00	\$21.52	\$0.89	316,170	673,024
2011	29,953	42,550	\$647,368.20	\$15.21	\$0.62	474,906	1,044,184
% Change	42.40%	52.50%	7.80%	-29.30%	-30.30%	50.20%	55.10%
Change	8,913	14,643	\$46,944.20	-\$6.31	-\$0.27	158,736	371,160

Members Demographics for Fiscal Year 2011




Top Prescribers of Anti-Emetic Products by Claims: FY 2010



Prior Authorization of Anti-Emetics

There were a total of 1,305 petitions submitted for PBPA category during fiscal year 2011. The following chart shows the status of the submitted petitions.

Status of Petitions for Select Anti-Emetic Medications: FY 2011



Market News and Update

9/15/2011 - The U.S. Food and Drug Administration (FDA) informed the public of an ongoing safety review of the anti-nausea drug Zofran® (ondansetron, ondansetron hydrochloride and their generics). Ondansetron may increase the risk of developing abnormal changes in the electrical activity of the heart, which can result in a potentially fatal abnormal heart rhythm.ⁱ

During 2011, the American Society of Clinical Oncology also updated their guidelines on anti-emetics when used with certain chemotherapy agents with high, medium, and low risk of nausea/vomiting.ⁱⁱ

Anticipated Patent Expirations:

- Emend® – listed patents expire from 2012 to 2018

Conclusion and Recommendations

The College of Pharmacy recommends no changes to the current prior authorization of select anti-emetic agents.

Utilization Details of Select Anti-Emetics: Fiscal Year 2011

CHEMICAL NAME	BRAND NAME	CLAIMS	DAYS	MEMBERS	COST	CLAIMS/MEMBER	COST/DAY	% COST
Ondansetron	ONDANSETRON TAB 4MG ODT	22,428	519,580	18,050	\$166,490.83	1.24	\$0.32	25.72%
Ondansetron	ONDANSETRON TAB 4MG	7,676	201,997	5,752	\$76,587.89	1.33	\$0.38	11.83%
Ondansetron	ONDANSETRON TAB 8MG ODT	5,359	146,293	3,554	\$49,264.54	1.51	\$0.34	7.61%
Ondansetron	ONDANSETRON TAB 8MG	3,966	109,929	2,536	\$38,172.32	1.56	\$0.35	5.90%
Ondansetron	ONDANSETRON SOL 4MG/5ML	2,675	58,282	2,197	\$173,835.46	1.22	\$2.98	26.85%
Aprepitant	EMEND PAK 80 & 125	127	2,405	55	\$54,735.14	2.31	\$22.76	8.46%
Granisetron	GRANISETRON TAB 1MG	76	889	16	\$7,486.43	4.75	\$8.42	1.16%
Ondansetron	ONDANSETRON INJ 4MG/2ML	68	341	25	\$1,066.96	2.72	\$3.13	0.16%
Dronabinol	DRONABINOL CAP 5MG	55	1,487	26	\$28,229.56	2.12	\$18.98	4.36%
Dronabinol	DRONABINOL CAP 10MG	51	1,530	9	\$38,919.96	5.67	\$25.44	6.01%
Dronabinol	DRONABINOL CAP 2.5MG	40	1,207	18	\$8,879.78	2.22	\$7.36	1.37%
Ondansetron	ONDANSETRON INJ 40/20ML	13	111	8	\$593.61	1.63	\$5.35	0.09%
Aprepitant	EMEND CAP 80MG	9	46	4	\$1,780.66	2.25	\$38.71	0.28%
Granisetron	SANCUSO DIS 3.1MG	4	84	1	\$1,312.52	4	\$15.63	0.20%
Ondansetron	ZOFRAN INJ 4MG/2ML	3	3	1	\$12.54	3	\$4.18	0.00%
TOTAL		42,550	1,044,184	29,953	\$647,368.20	1.42	\$0.62	100%

*Total number of unduplicated members

ⁱ <http://www.fda.gov/Drugs/DrugSafety/ucm271913.htm>

ⁱⁱ <http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Guidelines/Clinical+Practice+Guidelines/Antiemetics%3A+American+Society+of+Clinical+Oncology+Clinical+Practice+Guideline+Update>